Company: BOLT
Filing Date: 2025-04-15
Form Type: DEF 14A
Source: 0000950170-25-054294
Chunk: 13

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-04-15
Form: DEF 14A
Chunk 13
---
 known to us, file an additional Form 8-K to publish the final results.

<div align='center'>6</div>

PROPOSAL 1 : ELECTION OF DIRECTORS Our Board currently consists of six directors and is divided into three classes, designated as Class I, Class II and Class III. Under our Amended and Restated Certificate of Incorporation, our Board is authorized to assign its members in office to each class. Each class has a term of three years. There are currently two directors in Class I, Laura Berner and Brian O'Callaghan, whose terms of office are scheduled to expire at the 2025 Annual Meeting of Stockholders. Each of Ms. Berner and Mr. O'Callaghan have been nominated for election at the 2025 Annual Meeting of Stockholders, at the recommendation of our Nominating and Governance Committee. Proxies cannot be voted for a greater number of persons than the number of nominees named in this proposal. Any vacancies on our Board resulting from death, resignation, disqualification, removal or other causes, and any newly created directorships resulting from any increase in the number of directors, shall be filled by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board. Any director elected to fill a vacancy shall hold office for the remainder of the unexpired term in which the vacancy occurred or newly created directorship was created and until such director’s successor shall have been elected and qualified. Our bylaws provide for a plurality voting standard for the election of directors. Under this voting standard, the director nominees receiving the highest number of affirmative votes cast at the Annual Meeting are elected as directors. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the three nominees named below. If any of Ms. Berner and Mr. O'Callaghan become unavailable for election as a result of an unexpected occurrence, shares that would otherwise be voted for such director will be voted for the election of a substitute nominee proposed by the Nominating and Corporate Governance Committee and nominated by the Board. Ms. Berner and Mr. O'Callaghan have agreed to serve if elected. Our management has no reason to believe that any of Ms. Berner or Mr. O'Callaghan will be unable to serve. If elected at the Annual Meeting, each of Ms. Berner or Mr. O'Callaghan will serve until the earliest of the 2028 Annual Meeting of Stockholders